AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18636543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-volume preload (250 ml/171 kcal)
Number of subjects: 30
Study 18636543 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating disorder participants
Number of subjects: 30
Study 18636543 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 30
Study 16318999 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 genotype in ICVD group
Number of subjects: 142
Study 16318999 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1 genotype in ICVD group
Number of subjects: 142
Study 16318999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis for GSTM1 and GSTT1 genotypes in ICVD for smoking status
Number of subjects: 142
Study 15146227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and cyclophosphamide
Number of subjects: 88
Study 15146227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel
Number of subjects: 88
Study 15146227 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported peripheral neuropathy and functional status scales
Number of subjects: 88
Study 15146227 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status scale
Number of subjects: 88
Study 15146227 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy scale
Number of subjects: 88
Study 11342902 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 6 intravesical instillations every 6 months for 2 years
Number of subjects: 131
Study 11342902 — intervention group
Group type: COMPARATOR
Intervention: Control group with no maintenance therapy
Number of subjects: 131
Study 11342902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 131
Study 10480684 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (first degree relative)
Number of subjects: 702
Study 10480684 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (more than one family member affected)
Number of subjects: 702
Study 10480684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling history of colorectal cancer
Number of subjects: 702
Study 10480684 — intervention group
Group type: EXPERIMENTAL
Intervention: High parity
Number of subjects: 702
Study 10480684 — intervention group
Group type: COMPARATOR
Intervention: Exogenous hormonal factors (hormone replacement therapy)
Number of subjects: 702
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine (PC20 < or = 8.0 mg/ml)
Number of subjects: 0
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (delta % FEV1 < or = 10%)
Number of subjects: 0
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 0
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: BHR to histamine
Number of subjects: 0
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: BHR to exercise
Number of subjects: 0
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial challenge testing
Number of subjects: 0
Study 8747798 — intervention group
Group type: EXPERIMENTAL
Intervention: BHR
Number of subjects: 0
Study 2676258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (population hypertension control programs)
Number of subjects: 0
Study 2676258 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 0
Study 354916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (30 mg or 60 mg)
Number of subjects: 60
Study 354916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31389524 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated fasting
Number of subjects: 33
Study 28681506 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2245035 80 ng
Number of subjects: 42
Study 28681506 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2245035 20 ng
Number of subjects: 42
Study 28681506 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2245035 20 ng and 80 ng
Number of subjects: 42
Study 28681506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 26049675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red blood cell units stored seven days or less
Number of subjects: 2430
Study 26049675 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard delivery policy, red blood cell units stored about three weeks)
Number of subjects: 2430
Study 23778783 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high protein diets
Number of subjects: 685
Study 23778783 — intervention group
Group type: COMPARATOR
Intervention: Low protein diets
Number of subjects: 685
Study 23778783 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index diets
Number of subjects: 685
Study 23778783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diets
Number of subjects: 685
Study 21712619 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tenoxicam
Number of subjects: 48
Study 21712619 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of ibuprofen
Number of subjects: 48
Study 21712619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19944984 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stent placement
Number of subjects: 37
Study 19944984 — intervention group
Group type: COMPARATOR
Intervention: Nasolacrimal cryoplasty
Number of subjects: 37
Study 16924340 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforce resin-based cement
Number of subjects: 24
Study 16924340 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 24
Study 16924340 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoFill + gutta-percha
Number of subjects: 24
Study 16924340 — intervention group
Group type: COMPARATOR
Intervention: Gutta-percha alone (no cement)
Number of subjects: 24
Study 15322855 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 4 weeks
Number of subjects: 18
Study 15322855 — intervention group
Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 18
Study 15322855 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 18
Study 11385163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine monotherapy (2 x 250 mg daily)
Number of subjects: 243
Study 11385163 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (2 x 250 mg ticlopidine plus 100 mg aspirin daily)
Number of subjects: 243
Study 9435797 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy alone
Number of subjects: 257
Study 9435797 — intervention group
Group type: COMPARATOR
Intervention: Shoulder movement alone
Number of subjects: 257
Study 9435797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both physiotherapy and shoulder movement
Number of subjects: 257
Study 9435797 — intervention group
Group type: COMPARATOR
Intervention: Neither physiotherapy nor shoulder movement
Number of subjects: 257
Study 9435797 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder movement (in both physiotherapy and shoulder movement groups)
Number of subjects: 257
Study 9617710 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-radioactive polymerase chain reaction (PCR) procedure to detect (CTG)n repeat expansion in DM patients
Number of subjects: 24
Study 9617710 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-radioactive PCR for prenatal diagnosis in pregnant DM mothers
Number of subjects: 24
Study 2493366 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 12
Study 2493366 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg, at -8 hr; 50 mg, -1 hr)
Number of subjects: 12
Study 2493366 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of Misoprostol and Indomethacin
Number of subjects: 12
Study 772665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antigen (1 ml a day for four weeks)
Number of subjects: 110
Study 772665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml a day for four weeks)
Number of subjects: 110
Study 31992217 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based videoconferencing program (using LINE app), once a week for 6 months.
Number of subjects: 62
Study 31992217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smartphone-based videoconferencing program).
Number of subjects: 62
Study 30102874 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 12
Study 30102874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28800182 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME‐TQ intervention
Number of subjects: 35
Study 25924711 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, intensive resistance exercise program (1 year)
Number of subjects: 148
Study 25924711 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 148
Study 23512818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 39
Study 23512818 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 39
Study 23512818 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 21615623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 15 mg
Number of subjects: 37
Study 21615623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 18805583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (900 mg twice daily)
Number of subjects: 27
Study 18805583 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg twice daily)
Number of subjects: 27
Study 17020428 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor therapy
Number of subjects: 0
Study 15288916 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered QLQ-SAT32
Number of subjects: 123
Study 15288916 — intervention group
Group type: COMPARATOR
Intervention: Interview-administered QLQ-SAT32
Number of subjects: 123
Study 11704591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment in CF subjects
Number of subjects: 14
Study 11704591 — intervention group
Group type: EXPERIMENTAL
Intervention: No ibuprofen treatment in CF subjects
Number of subjects: 14
Study 11704591 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 14
Study 11704591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in both CF and control subjects
Number of subjects: 14
Study 9415633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (40 mg/day)
Number of subjects: 38
Study 9415633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8302450 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA (infusor Baxter) with morphine i.v. (basal bolus 0.05 mg/kg, loading doses 1 mg every 6‐15')
Number of subjects: 84
Study 8302450 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA (morphine i.v., basal bolus 0.07 mg/kg, bolus PCA 0.007 mg/kg lock‐out 15')
Number of subjects: 84
Study 8302450 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA
Number of subjects: 84
Study 3518333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine nasal spray
Number of subjects: 25
Study 3518333 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal spray (Control)
Number of subjects: 25
Study 31358329 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 848
Study 31358329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study 29763783 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (2 mg/unit BMI)
Number of subjects: 82
Study 29763783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1.5 mg)/Corticotropin-releasing factor (1 μg/kg)
Number of subjects: 82
Study 27606561 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximating graft edges (AP)
Number of subjects: 19
Study 27606561 — intervention group
Group type: COMPARATOR
Intervention: Overlapping graft edges (OV)
Number of subjects: 19
Study 27606561 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Vancouver Scar Score (VSS)
Number of subjects: 19
Study 27606561 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual domain VSS scores (height, pliability, vascularity, pigmentation)
Number of subjects: 19
Study 23897905 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning-based treadmill training for 30 minutes, 12 sessions over 4 weeks
Number of subjects: 30
Study 23897905 — intervention group
Group type: COMPARATOR
Intervention: Regular treadmill training for 30 minutes followed by a 10-minute general exercise program, 12 sessions over 4 weeks
Number of subjects: 30
Study 22389937 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT 3 hr/day for 21 days
Number of subjects: 18
Study 22389937 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT 6 hr/day for 21 days
Number of subjects: 18
Study 21094358 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal electrocardiograms (ECG)
Number of subjects: 10101
Study 21094358 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite ECG Q-wave myocardial infarction (MI)
Number of subjects: 10101
Study 21094358 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG evidence of left ventricular hypertrophy
Number of subjects: 10101
Study 21094358 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal electrocardiograms
Number of subjects: 10101
Study 21094358 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related abnormal electrocardiograms
Number of subjects: 10101
Study 21094358 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina and coronary artery bypass graft surgery
Number of subjects: 10101
Study 17964008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) for three months in addition to dietary counselling (DC)
Number of subjects: 80
Study 17964008 — intervention group
Group type: COMPARATOR
Intervention: Only dietary counselling (DC)
Number of subjects: 80
Study 15684311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (GW572016) administered orally once daily continuously
Number of subjects: 33
Study 12862418 — intervention group
Group type: COMPARATOR
Intervention: Low dose recombinant human IL-12 (rhIL-12) at doses of 10, 30, and 100 ng/kg, administered subcutaneously or intravenously
Number of subjects: 28
Study 12862418 — intervention group
Group type: EXPERIMENTAL
Intervention: Melan-A26-35 and influenza matrix58-66 peptides administered intradermally on weeks 1, 2, 3, 4, and 9
Number of subjects: 28
Study 12862418 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsies of accessible tumors
Number of subjects: 28
Study 12862418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rhIL-12 (10-100 ng/kg)
Number of subjects: 28
Study 10568486 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 microg/g) applied twice a day with oral etretinate (50 mg/day)
Number of subjects: 86
Study 10568486 — intervention group
Group type: COMPARATOR
Intervention: Oral etretinate (50 mg/day) alone
Number of subjects: 86
Study 8739825 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 100 mg orally daily for 8 days
Number of subjects: 15
Study 8739825 — intervention group
Group type: COMPARATOR
Intervention: Tirilazad mesylate alone
Number of subjects: 15
Study 8739825 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital + tirilazad
Number of subjects: 15
Study 1745508 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Number of subjects: 80
Study 1745508 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 80
Study 7033825 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (mean daily intake of 4.5 mg)
Number of subjects: 28
Study 7033825 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (mean daily intake of 56.5 mg)
Number of subjects: 28
Study 31317805 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30256747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved placental membrane (CPM) applied weekly
Number of subjects: 26
Study 30256747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved placental membrane (CPM)
Number of subjects: 26
Study 30256747 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (SWC)
Number of subjects: 26
Study 27324887 — intervention group
Group type: EXPERIMENTAL
Intervention: RI‐002 (10% Liquid Intravenous Immunoglobulin containing high titer neutralizing antibody to RSV)
Number of subjects: 59
Study 25181918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-implant LVEF < 22% (T(low)); n = 128
Number of subjects: 366
Study 25181918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-implant LVEF 22% to 28% (T(middle)); n = 121
Number of subjects: 366
Study 25181918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-implant LVEF > 28% (T(high)); n = 117
Number of subjects: 366
Study 22245668 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ-SP
Number of subjects: 82
Study 22245668 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ-SP-PQ
Number of subjects: 82
Study 22245668 — intervention group
Group type: EXPERIMENTAL
Intervention: MQ-AS
Number of subjects: 82
Study 22245668 — intervention group
Group type: EXPERIMENTAL
Intervention: MQ-AS-PQ
Number of subjects: 82
Study 19155454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - 1 packet per day (92 g, 500 kcal/d) for 3 months in intervention villages.
Number of subjects: 3166
Study 19155454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) in nonintervention villages.
Number of subjects: 3166
Study 18260975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (AT)
Number of subjects: 60
Study 18260975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (AC)
Number of subjects: 60
Study 18260975 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (TL)
Number of subjects: 60
Study 15465841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH), 3 units planned
Number of subjects: 160
Study 15465841 — intervention group
Group type: COMPARATOR
Intervention: No acute normovolaemic haemodilution (no ANH)
Number of subjects: 160
Study 15465841 — intervention group
Group type: COMPARATOR
Intervention: Transfusion protocol (historical controls)
Number of subjects: 160
Study 11294535 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Nd‐YAG laser fulguration
Number of subjects: 1
Study 9589818 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol powder 50 micrograms twice daily
Number of subjects: 451
Study 9589818 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 micrograms four times daily
Number of subjects: 451
Study 9589818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 7978586 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 to 15 micrograms/kg of OTFC
Number of subjects: 30
Study 7978586 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 to 20 micrograms/kg of OTFC
Number of subjects: 30
Study 2563409 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐alanyl‐L‐glutamine (54 mg peptide‐N/kg per day)
Number of subjects: 12
Study 2563409 — intervention group
Group type: COMPARATOR
Intervention: Control solution (alanine‐N and glycine‐N)
Number of subjects: 12
Study 51141 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1 g six-hourly for fourteen days
Number of subjects: 124
Study 51141 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 124
Study 31215756 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist bridging service
Number of subjects: 600
Study 31215756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 600
Study 29208797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride varnish applied three times a week for 1 year
Number of subjects: 200
Study 29208797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 26001563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (37.5, 125, 250 mg)
Number of subjects: 0
Study 26001563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22934678 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (1 day of training including lectures, interactive sessions, multimedia demonstrations, and role play)
Number of subjects: 95
Study 22934678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-service intervention (monetary compensation for counselling)
Number of subjects: 95
Study 22934678 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 95
Study 22934678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation counselling
Number of subjects: 95
Study 21618158 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-braked ergometer (AE)
Number of subjects: 41
Study 18056796 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sexist humor (sexist jokes)
Number of subjects: 0
Study 18056796 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sexist comedy skits
Number of subjects: 0
Study 18056796 — intervention group
Group type: COMPARATOR
Intervention: Neutral comedy skits
Number of subjects: 0
Study 18056796 — intervention group
Group type: COMPARATOR
Intervention: Nonhumorous sexist statements
Number of subjects: 0
Study 17126638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (250 mL for 7 days)
Number of subjects: 7
Study 17126638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 7
Study 15574079 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (16 mg.day(‐1))
Number of subjects: 0
Study 15574079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11350882 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-CEA B7.1 vaccine alone
Number of subjects: 60
Study 11350882 — intervention group
Group type: COMPARATOR
Intervention: ALVAC-CEA B7.1 vaccine with GM-CSF
Number of subjects: 60